Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Multiple Sclerosis
 More »

  • AbbVie Expands Galapagos Collaboration to Include Crohn's Disease
    ... AbbVie's pipeline includes mid- to late-stage clinical programs for diseases that include hepatitis C, rheumatoid arthritis, psoriasis, multiple sclerosis, Alzheimer's disease, ...
    5-17-2013
  • Seasoned Drugs Offer Therapeutic Gold Mine
    ... Biovista has already repositioned two drugs for the progressive form of multiple sclerosis (MS), which has had few treatment options. Most MS drugs, for treatment of the ...
    5-15-2013
  • Pharma Builds Bridges with Advocacy Groups
    ... Big pharmas can also learn about engagement from Acorda Therapeutics, which markets Ampyra® to improve walking in people with multiple sclerosis, as well as Zanaflex® capsules ...
    5-7-2013
  • GEN Congressional Hall of Fame
    ... Visionary Award, 2010 American Association of Orthopedic Surgeons, Congressional Leadership Award, 2009 Multiple Sclerosis Society, House Legislator of the Year, 2008 Rep. ...
    5-1-2013
  • EMD Serono Expanding R&D Hub in Billerica, MA
    The company is striving to build expertise in oncology, immuno-oncology, and immunology, in addition to further strengthening its solid market position in multiple sclerosis. In ...
    4-18-2013
  • Pfenex and Agila Biotech Target Biosimilars
    The lead product for the joint venture is Interferon beta-1b, a biosimilar to Betaseron®, indicated for relapsing-remitting and secondary-progressive forms of multiple sclerosis. ...
    4-16-2013
  • Top 20 Best-Selling Drugs Approved and Launched During 2012
    (€7 million) 4 Marketer(s): Sanofi (Genzyme) Indication(s): Relapsing forms of multiple sclerosis Date of FDA approval: September 12, 2012 #15. Fycompa® (perampanel) 2012 sales: ...
    4-4-2013
  • Clock Ticking in Elan Takeover Battle
    Elan or declare it will give up plans to buy the biotech giant for more than double what it gained from selling its 50% share in the multiple sclerosis drug Tysabri to Biogen Idec. ...
    4-3-2013
  • Biogen Idec Prepares to Launch 4th MS Drug
    fumarate) in the U.S. "in the coming days" after winning FDA approval for first-line oral treatment of relapsing multiple sclerosis (MS). Tecfidera is Biogen Idec's fourth MS drug. ...
    3-28-2013
  • Medicine: Getting Personal
    ... model, but instead scale-out, producing multiple individualized products in parallel. ... in patients with amyotrophic lateral sclerosis (ALS), for example. 6. Smith and Nephew ...
    3-15-2013
  • Top 10 Biopharma Layoffs of 2012
    ... cladribine for multiple sclerosis and Erbitux for lung tumors; Geneva campus shutdown part of a cost-cutting consolidation following the company's 2006 acquisition of Serono. ...
    3-15-2013
  • PhRMA Report: 907 Drugs, Vaccines in Development
    Another 71 medicines were for autoimmune diseases including lupus, multiple sclerosis, and rheumatoid arthritis, up from 69 two years ago. And the fourth-largest disease category, ...
    3-14-2013
  • Receptos Licenses AbbVie Antibody for Co-Development
    ... of the sphingosine 1-phosphate 1 receptor (S1P1R) pathway, a G protein-coupled receptor (GPCR) target for relapsing multiple sclerosis (RMS) and inflammatory bowel disease. ...
    3-13-2013
  • Merck KGaA Offers Sunny Forecast for 2013, 2014
    largest-selling product, the drug Rebif® for relapsing forms of multiple sclerosis, accounted for a 7.5% rise in sales of the product to about €1.9 billion (about $2.5 billion). ...
    3-8-2013
  • Avanir to Screen Veterans for Pseudobulbar Affect Symptoms
    Avanir's Nuedexta was approved by the FDA in 2010 as a treatment for pseudobulbar affect. PBA occurs when a TBI or other neurological condition, such as multiple sclerosis, Lou ...
    3-6-2013
  • More »

    Journal Articles

  • Using an Automated Recruitment Process to Generate an Unbiased...
    Deborah M. Miller, R. Fox, A. Atreja, S. Moore, J.-C. Lee, A.Z. Fu, A. Jain, W. Saupe, S. Chakraborty, M. Stadtler, R.A. Rudick
    Telemedicine and e-Health
    Using an Automated Recruitment Process to Generate an Unbiased Study Sample of Multiple Sclerosis Patients Telemedicine and e-Health The Mellen Center Care On-line (MCCO), a ...
  • Mesenchymal Stem Cells Enhance the Engraftment and Myelinating...
    Massimiliano Cristofanilli, Violaine K. Harris, Aaron Zigelbaum, Andrea M. Goossens, Amy Lu, Hannah Rosenthal, Saud A. Sadiq
    Stem Cells and Development
    Mesenchymal Stem Cells Enhance the Engraftment and Myelinating Ability of Allogeneic Oligodendrocyte Progenitors in Dysmyelinated Mice Stem Cells and Development Multiple sclerosis ...
  • Mesenchymal Stem Cells Prime Proliferating Adult Neural Progenitors...
    Carolin Steffenhagen, Franz-Xaver Dechant, Eleni Oberbauer, Tanja Furtner, Norbert Weidner, Patrick Küry, Ludwig Aigner, Francisco J. Rivera, Franz Xaver Dechant, Patrick Kuery
    Stem Cells and Development
    The present findings underscore the potential use of MSCs in cell therapies for remyelination such as in multiple sclerosis and spinal cord injury. Moreover, they urge the ...
  • Mouse Mesenchymal Stem Cells Suppress Antigen-Specific TH Cell...
    Tobias V. Lanz, Christiane A. Opitz, Peggy P. Ho, Ankur Agrawal, Christian Lutz, Michael Weller, Andrew L. Mellor, Lawrence Steinman, Wolfgang Wick, Michael Platten
    Stem Cells and Development
    Due to their immunosuppressive properties, human mesenchymal stem cells (hMSC) represent a promising tool for cell-based therapies of autoimmune diseases such as multiple sclerosis ...

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll